UNITAID Drug Purchase Facility

Date of commitment: 
September 2006


An international drug purchase facility, designed to contribute to scaling up access to treatment for HIV/AIDS, malaria and tuberculosis, primarily for people in low-income countries, by leveraging price reductions for quality diagnostics and medicines and accelerating the pace at which these are made available. UNITAID provides a sustained and strategic market intervention that aims both to decrease the price of medicines for priority diseases and to increase the supply of drugs and diagnostics. UNITAID collects most of its funds from a levy or 'tax' on airline tickets. Originally founded by Brazil, Chile, France, Norway and the United Kingdom.


No numerical targets were set.


  • More than US$ 1 billion of UNITAID funding supports 17 project areas in 94 countries.
  • UNITAID finances HIV, TB, and malaria projects in 94 countries. It is the largest funder of pediatric HIV/AIDS drugs, funding 85% of all pediatric ARVs globally. According to UNITAID, it has also achieved price reductions of up to 80% on leading pediatric ARVs, and has helped to reduce the price of second-line treatment for HIV/AIDS—from US$1,500 per patient per year in 2006 to an average of US$450 per patient per year as of May 2012.
  • UNITAID raised a total of US$1.6 billion in donor contributions between 2007 and 2011. For the years 2012 and 2013, France has committed US$132 million annually, and the United Kingdom (UK) has committed US$85 million annually.


No numerical targets were set, thus it is difficult to measure a gap.